Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Strata Critical Medical (SRTA) · oqro.io/stocks/SRTA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about Strata Critical Medical insider trading
Have Strata Critical Medical insiders bought shares recently?
Yes. Insiders of Strata Critical Medical (SRTA) filed 1 open-market purchase in the last 90 days; the latest was filed on Nov 9, 2026.
How often do Strata Critical Medical insiders buy and sell shares?
Since 2021, Strata Critical Medical insiders reported 6 open-market purchases and 136 sales on Forms 4 and 5, with purchases in 4 different years, most recently 2026.
Who is selling Strata Critical Medical stock?
No open-market sale by an insider of Strata Critical Medical (SRTA) was filed with the SEC in the last 90 days.
Do members of Congress trade SRTA?
No trade in Strata Critical Medical (SRTA) was disclosed by a member of Congress in the last 12 months.
When does Strata Critical Medical report its next results?
Strata Critical Medical's next results are expected on Mar 1, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
SRTA price and disclosed activity
+14.5% (+$0.61) from Nov 19, 2025 to Nov 19, 2026 · adjusted daily closes
Adjusted close went from $4.22 on Nov 19, 2025 to $4.83 on Nov 19, 2026 (+14.5%). Disclosed in this range: 1 insider trade, 0 pre-arranged insider sales, 0 Congress trades, and 4 13F position changes for 4 quarters ending in it.
$3$4$6$7$4.83
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 1 trade in this range as a list
Andrew Lauck, Director · Insider purchase, about $10Ktraded Nov 5, 2026, filed Nov 9, 2026
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Services-Health Services company based in New York, Ny.
Last 12 months
+14.4%
S&P 500 +8.0% over the same dates
Market value
$431M
Close of Nov 19, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 4.55M shares sold short (5.1% of shares outstanding), +0.3% vs the previous count, 5.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
A Strata Critical Medical insider told the SEC about a plan to sell $517K of Strata Critical Medical shares around Oct 2, 2026. The shares were not acquired as compensation. That is 0.1% of all Strata Critical Medical shares.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Latest results: quarter ending Sep 30, 2026
Revenue
$74.1M
+50.3% vs the same quarter a year earlier
Free cash flow, last 12 months
$806K
This quarter $9.06M, a year earlier −$40.2M
Net debt
—
Debt —, cash $35.1M, at Sep 30, 2026
Net income, last 12 months
−$24.8M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 3, 2026.
Since Nov 17, 2025, SRTA is up 8.5% and the index fund is up 7.5%: about the same. Traders call a stock that beats the index over a period a relative-strength leader.
How much SRTA moves
A usual day
±2.0%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
6.2%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−9.1%Jan 26, 2026
Largest one-day rise
+17.6%Nov 4, 2026
Deepest fall of the year
−33.8%From the close of May 28, 2026 to Oct 14, 2026.
Days of 5% or more
27Out of 252 sessions, in either direction.
Beta 1.9(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 248 trading days (1 = in step with it).
Insider buying and selling since 2021
Insiders of Strata Critical Medical reported 6 open-market purchases and 136 sales since 2021; purchases in 4 different years, most recently 2026.
Year
Bought
Sold
2026
$10K1×1 trade
—
2025
—
$1.81M6×6 trades
2024
$38K2×2 trades
$9.29M31×31 trades
2023
$160K1×1 trade
$3.24M61×61 trades
2022
—
$8.47M38×38 trades
2021
$20.1M2×2 trades
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Strata Critical Medical filed 1 open-market purchase (about $10K, in 1 filing, by 1 person) and 0 open-market sales (about $0, in 0 filings, by 0 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 16 open-market sales (about $3.12M, in 12 filings). (Strata Critical Medical on OQRO)
Funds and stakes. Fund 13F filings recorded in the 12 months show 2 new or larger positions and 2 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter. Third Point LLC disclosed a 5.8% stake in SRTA (filed Oct 15, 2026).
Contracts, lobbying and filings. FINRA short interest for SRTA on the settlement date of Oct 30, 2026 was 4,550,210 shares (+0.27% on the previous report), about 4.98 days of average volume. In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: none on record; the largest that shrank: ARK Investment Management (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Strata Critical Medical filed a Form 8-K on Nov 3, 2026 (Item 2.02) that OQRO classes as: reported its results. Strata Critical Medical filed a Form 8-K on Dec 3, 2025 (Items 5.02, 7.01) that OQRO classes as: changed a top executive or board member, and shared information with investors.
Who holds it. 139 funds reported a stake in Strata Critical Medical in their 13F for Q2 2026. The largest by value: Third Point LLC (9.0% of the value reported), Northern Right Capital Management, L.P. (8.8% of the value reported), BlackRock, Inc. (8.7% of the value reported).
Deals. Strata Critical Medical is the target of Joby Aviation; status: announced, first on record Sep 11, 2026.
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. An 8-K item says what the company reported, not what it means for the share price.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Strata Critical Medical filed 1 open-market purchase (about $10K, in 1 filing, by 1 person) and 0 open-market sales (about $0, in 0 filings, by 0 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 16 open-market sales (about $3.12M, in 12 filings).
The largest purchase: Andrew Lauck, Director, about $10K, filed Nov 9, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 2 new or larger positions and 2 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Third Point LLC disclosed a 5.8% stake in SRTA (filed Oct 15, 2026).
Contracts, lobbying and filings
FINRA short interest for SRTA on the settlement date of Oct 30, 2026 was 4,550,210 shares (+0.27% on the previous report), about 4.98 days of average volume.
In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: none on record; the largest that shrank: ARK Investment Management (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press
Strata Critical Medical filed a Form 8-K on Nov 3, 2026 (Item 2.02) that OQRO classes as: reported its results.
Strata Critical Medical filed a Form 8-K on Dec 3, 2025 (Items 5.02, 7.01) that OQRO classes as: changed a top executive or board member, and shared information with investors.
The company's own opening sentence of that report reads: "On December 2, 2025, the board of directors (the 'Board') of Strata Critical Medical, Inc. (the 'Company') expanded the size of the Board from eight directors to nine directors and appointed William L. Cook, III to serve as a Cla..."
Last 30 days
Written by software from the filings listed below · Oct 26, 2026
Contracts, lobbying and filings. FINRA short interest for SRTA on the settlement date of Sep 30, 2026 was 4,331,692 shares (-0.62% on the previous report), about 6.07 days of average volume. In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Royce & Associates LP (increased, 316,561 shares); the largest that shrank: ARK Investment Management (reduced, 4,724,429 shares); Amova Asset Management Americas, Inc. (reduced, 665,261 shares). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Press coverage listed by Finnhub: "Strata Critical Medical and 3 More Stocks See Action From Activist Investors" (Yahoo, Oct 23, 2026). Press coverage listed by Finnhub: "Strata Critical Medical Schedules Third Quarter 2026 Earnings Conference Call" (Yahoo, Oct 23, 2026).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Third Point LLC disclosed a 5.8% stake in SRTA (filed Oct 15, 2026).
Contracts, lobbying and filings
FINRA short interest for SRTA on the settlement date of Sep 30, 2026 was 4,331,692 shares (-0.62% on the previous report), about 6.07 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Royce & Associates LP (increased, 316,561 shares); the largest that shrank: ARK Investment Management (reduced, 4,724,429 shares); Amova Asset Management Americas, Inc. (reduced, 665,261 shares). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press
Press coverage listed by Finnhub: "Strata Critical Medical and 3 More Stocks See Action From Activist Investors" (Yahoo, Oct 23, 2026).
Press coverage listed by Finnhub: "Strata Critical Medical Schedules Third Quarter 2026 Earnings Conference Call" (Yahoo, Oct 23, 2026).
Press coverage listed by Finnhub: "Third Point's Daniel Loeb Urges Strata Critical Medical To Explore Strategic Alternatives Including Potential Sale" (Benzinga, Oct 15, 2026).
SRTA closed at $4.66 on Oct 23, 2026, the last session on or before the end of the period.
From Sep 23, 2026 to Oct 23, 2026, the close moved from $5.38 to $4.66, a change of −13.4%.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Records
Strata Critical Medical filed a Form 8-K on Dec 2, 2025 (Item 2.01) that OQRO classes as: completed buying or selling a business or assets.
The company's own opening sentence of that report reads: "The information set forth in the 'Explanatory Note' of this Amendment is incorporated by reference into this"
Press coverage listed by Finnhub: "Strata Critical Medical to Present at the UBS Global Healthcare Conference" (Yahoo, Nov 3, 2026).
Press coverage listed by Finnhub: "Strata Critical Medical Q3 Earnings Call Highlights" (Yahoo, Nov 3, 2026).
Press coverage listed by Finnhub: "Strata Critical Medical Announces Third Quarter 2026 Results" (Yahoo, Nov 3, 2026).
SRTA closed at $4.96 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $4.54 to $4.96, a change of +9.3%.
Who holds it
139 funds reported a stake in Strata Critical Medical in their 13F for Q2 2026. The largest by value: Third Point LLC (9.0% of the value reported), Northern Right Capital Management, L.P. (8.8% of the value reported), BlackRock, Inc. (8.7% of the value reported).
Deals
Strata Critical Medical is the target of Joby Aviation; status: announced, first on record Sep 11, 2026.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Mar 3, 2026. Read the filing
By business segment
Logistics$177M90%
+20% on the year before ($147M)
Clinical$20.3M10%
$0 the year before
Total revenue$197M+34%
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 9,000 words.
From “Overview”, in the company's words
Strata Critical Medical, Inc. (f/k/a Blade Air Mobility, Inc.) (“Strata” or the “Company”) is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates one of the nation’s largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated “one call” solution for donor organ recovery. Strata’s core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions (“Trinity”) and Keystone brands.
What the section covers (40 headings)
Overview
Logistics Segment
Clinical Segment
Sale of Passenger business
Acquisition of Keystone Perfusion Services, LLC
Our Business Model
Logistics Services
Clinical Services
Technology
Factors Affecting our Performance
Availability of Donor Organs
Ability to Attract and Retain Customers
Ability to Secure Aircraft Capacity
Ability to Hire, Train and Retain Clinicians
And 26 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 3, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
When insiders usually buy
Last results
Nov 3, 2026
Within the 30 days after it, until Dec 3, 2026
Next results, expected
Mar 1, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Strata Critical Medical's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Strata Critical Medical's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Off-exchange trading: 34.9% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (19.2% on ATS, 15.7% with other brokers), close to its 26-week average of 36.6%. Weeks of Sep 21 to Oct 16, 2026.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: INTELLIGENT CROSS LLC (17.2%), UBS ATS (15.3%), MS TRAJECTORY CROSS (ATS-1) (14.0%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Risk factors in the annual report
Latest annual report filed Mar 3, 2026, compared with the one filed Mar 13, 2025. Read the filing
New risk factors in the latest annual report (7 headings)
Any inability to realize the anticipated benefits of the sale of the Passenger business or acquisition of Keystone could negatively impact our stock price and our business and financial results.
We provide clinical services to our customers and perfusion staffing services to hospitals and health systems. We may be subject to negative publicity and reputational damage related to the provision of such services, as well as litigation, claims, investigations, and other proceedings, which could result in actions including substantial judgments, settlement costs, uninsured or underinsured liabilities, and other adverse consequences.
Our growth may depend on the adoption and effective utilization of integrated clinical and logistics workflows by our Medical Customers, and failure to achieve such adoption could adversely affect our business, financial condition, and results of operations.
The organ transportation and clinical services markets in which we operate are highly competitive, and increased competition could adversely affect our business, financial condition and results of operations.
Restrictive covenants in our Credit Agreement may restrict our ability to pursue our business strategies and we may incur substantial additional indebtedness in the future.
Employment-related claims or workforce litigation could result in significant costs and operational disruption.
Due to the effects of discontinued operations for the Passenger business, our historical financial results may not be comparable to current or future results.
No longer listed (14 headings from the year before)
Our Short Distance business concentrated in a small number of metropolitan areas and airports which makes us particularly susceptible to natural disasters, outbreaks and pandemics, economic, social, political, weather, growth constraints, and regulatory conditions or other circumstances affecting these metropolitan areas.
Our Medical product line relies on a concentrated number of key Medical Customers, including transplant centers, hospitals, and Organ Procurement Organizations.
The organ transportation market is highly competitive and some providers benefit from proprietary organ preservation technology or additional capabilities that could put us at a disadvantage.
The markets for our Passenger offerings are still in relatively early stages of growth, and if such markets do not continue to grow, grow more slowly than we expect, or fail to grow as large as we expect, our business, financial condition, and results of operations could be adversely affected.
The success of our Passenger segment will be highly dependent on our ability to effectively market and sell air transportation as a substitute for conventional methods of transportation.
If we are not able to successfully enter into new markets and offer new routes and services and enhance our existing offerings, our business, financial condition, and results of operations could be adversely affected.
We expect to face intense competition in the urban air mobility industry.
Legal proceedings (Item 3)
In the opinion of management, other than as described below, we are not involved in any claims, legal actions, or regulatory proceedings as of December 31, 2025, the ultimate disposition of which would have a material adverse effect on our consolidated financial position, results of operations, or cash flows. In February 2024, two putative class action lawsuits relating to the acquisition of Blade Urban Air Mobility, Inc. (“Old Blade”) were filed in the Delaware Court of Chancery. On April 16, 2024, these cases were consolidated under the caption Drulias et al. v. Affeldt, et al., C.A. No.
Source: SEC EDGAR, Form 10-K filed Mar 3, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Our prospects and operations may be adversely affected by changes in consumer preferences, discretionary spending, and other economic conditions that affect demand for our services.